HYL.BR Stock - Hyloris Pharmaceuticals S.A.
Unlock GoAI Insights for HYL.BR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.04M | $2.09M | $2.95M | $3.10M | $175,000 |
| Gross Profit | $9.81M | $1.99M | $2.86M | $2.99M | $30,000 |
| Gross Margin | 97.7% | 95.5% | 96.8% | 96.5% | 17.1% |
| Operating Income | $-7,130,000 | $-15,993,000 | $-11,638,000 | $-4,944,000 | $-7,025,000 |
| Net Income | $-6,342,000 | $-15,380,000 | $-11,906,000 | $-11,579,000 | $-7,146,000 |
| Net Margin | -63.2% | -736.9% | -403.5% | -374.0% | -4083.4% |
| EPS | $-0.22 | $-0.55 | $-0.44 | $-0.45 | $-0.28 |
Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. It also provides other products, such as post operation pain, dental indications, severe and recurring vulvovaginal candidiasis, acute myeloid leukemia and small cell lung cancer, IC/PBS, attention deficit hyperactivity disorder, and viral infection. Hyloris Pharmaceuticals SA was incorporated in 2012 and is headquartered in Liège, Belgium.
Visit WebsiteEarnings History & Surprises
HYL.BREPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Sep 25, 2025 | — | — | — | — |
Q2 2025 | Apr 23, 2025 | — | — | — | — |
Q1 2025 | Mar 21, 2025 | — | $-0.05 | — | — |
Q3 2024 | Sep 30, 2024 | — | $-0.05 | — | — |
Q3 2024 | Jul 5, 2024 | — | $-0.06 | — | — |
Q2 2024 | Jun 12, 2024 | — | $-0.06 | — | — |
Q1 2024 | Mar 14, 2024 | — | $-0.16 | — | — |
Q4 2023 | Dec 30, 2023 | — | $-0.16 | — | — |
Q3 2023 | Sep 7, 2023 | — | $-0.14 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.12 | — | — |
Q1 2023 | Mar 15, 2023 | — | $-0.12 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.12 | — | — |
Q3 2022 | Sep 1, 2022 | — | $-0.09 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.19 | — | — |
Q1 2022 | Mar 16, 2022 | — | $-0.13 | — | — |
Q4 2021 | Nov 16, 2021 | — | $-0.06 | — | — |
Q3 2021 | Aug 4, 2021 | — | $-0.16 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.32 | — | — |
Q1 2021 | Mar 9, 2021 | — | $-0.07 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.07 | — | — |
Latest News
Frequently Asked Questions about HYL.BR
What is HYL.BR's current stock price?
What is the analyst price target for HYL.BR?
What sector is Hyloris Pharmaceuticals S.A. in?
What is HYL.BR's market cap?
Does HYL.BR pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to HYL.BR for comparison